Prostate cancer LATITUDE Trial: Addition of Abiraterone to Standard Hormonal Therapy Improves Outcomes in Newly Diagnosed Metastatic Prostate Cancer Karim Fizazi, Institut Gustave Roussy, Villejuif, France, presented the results of the LATITUDE Trial (Abstract LBA3). Rationale Despite androgen-deprivation therapy, the adrenal glands and prostate cancer cells continue making small amounts of androgens. Abiraterone inhibits production of testosterone throughout the body … Read More
At ASCO June 2017: STAMPEDE Trial
Prostate cancer STAMPEDE Trial: Adding Abiraterone to Standard Treatment Improves Survival in Advanced Prostate Cancer Nick James, University of Birmingham, UK, presented the latest data at the 2017 ASCO Annual Meeting (Abstract LBA5003). The STAMPEDE clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the … Read More